


**Information on individuals nominated for appointment as directors in place of those whose terms have expired (Attachment No. 5).**

<b>Name-Surname</b>	: Dr. Shivatra Talchai	
<b>Age</b>	: 46 years	
<b>Nationality</b>	: Thai	
<b>Type of Directorship</b>	: Independent Director	
<b>Current Position</b>	: Independent Director and Audit Committee Member	
<b>Date of Appointment as Director</b>	: 27 July 2022 - Present	
<b>Years of Directorship</b>	: 3 years and 8 months (as of the Annual General Meeting of Shareholders)	
<b>Education</b>	: Bachelor's Degree • Biology (Honor), Wesleyan University, Connecticut, USA Master's Degree • Genomics & Computational Biology University of Pennsylvania, USA Doctoral Degree • Regenerative Medicine & Metabolic biology, Columbia University, New York, USA	
<b>Expertise</b>	: Expertise in biotechnology and metabolic diseases. Pioneer in stem cell research and tissue-specific induction. Holder of internationally recognized patents on intestinal stem cell applications for diabetes treatment	
<b>Training</b>	: • 2025 Audit Committee Seminar "In the Winds of Change", organized by EY Office Limited • 2010 Cold Spring Harbor Laboratory Stem Cell Course Cold Spring Harbor, New York, USA • 2010 – 2011 New York Stem Cell Innovator course level 2 & 3 New York Stem Cell Foundation Biosafety, USA	
<b>Director Training Program</b>	: 2022 Director Accreditation Program (DAP) Class 192	
<b>Work Experience (Past 5 Years)</b>	: • 2016 – Present Lecturer in Biology Chulabhorn Graduate Institute • 2019 – 2021 Special Lecturer in Regenerative Medicine Faculty of Medicine Siriraj Hospital, Mahidol University • 2018 – 2021 Special Lecturer in Tissue Engineering Faculty of Medicine, Chulalongkorn University • 2020 Advisor Forkhead BioTherapeutics, New York, USA • 2019: Member of the Academic Conference Committee in Neuroscience Chulabhorn Graduate Institute, Chulabhorn Royal Academy	

Meeting Attendance in 2024 : Board of Directors' Meetings: 6/6 meetings (100%)  
Audit Committee Meetings: 4/4 meetings (100%)

Shareholding in the Company : 155,000 shares (representing 0.0145% of all voting shares)

- Held by the director : 155,000 shares
- Held by Spouse/Minor Children : -None-

Director Nominee	Other Listed Companies		Other Non-Listed Companies		Positions in Competing / Related Businesses
	No.	Position	No.	Position	
Dr. Shivatra Talchai	-None-	-None-	-None-	-None-	-None-

**Additional Qualifications for the Nominated Independent Director (In accordance with the Notification of the Capital Market Supervisory Board No. TorJor. 39/2016)**

**Nature of Relationship**

- The nominee has no familial relationship, either by blood or legal registration, including as parents, spouse, siblings, and children, as well as spouses of children, with other directors, executives, major shareholders, controlling persons, or persons nominated to be directors, executives, or controlling persons of the Company or its subsidiaries.
- The nominee has not been appointed as a representative of any director of the Company, major shareholder or controlling person of the Company within the past two years.

**Conflicts of Interest with the Company (including the Company, its subsidiaries, associates, fellow subsidiaries, major shareholders, or controlling persons within the past two years)**

- The nominee is not and has not been a director involved in management, employee, staff member, salaried advisor, or controlling person of the Company, as defined under the Company's independent director qualifications.
- The nominee is not a professional service provider, including but not limited to an auditor, partner of an audit firm, legal advisor, or financial advisor.
- The nominee does not have and has not had any business relationship with the Company, nor is or has been a significant shareholder or controlling person of any entity having a business relationship with the Company, in a manner that may impede the exercise of independent judgment.


**Director Qualifications**

- The nominee possesses all qualifications as required by applicable laws and relevant regulations. Details are provided below.\*

**Performance in 2025**

- 1) Contributed to the formulation of the Company's policies, vision, mission, and strategic business plans, ensuring alignment with the Company's vision: "To be the most reliable advanced cell banking service provider in Asia."
- 2) Promoted good corporate governance and business ethics, ensuring compliance with applicable laws, regulations, and relevant requirements, while safeguarding the best interests of shareholders and all stakeholders.
- 3) Oversaw and monitored the Company's performance to ensure alignment with established targets, as well as compliance with applicable laws and regulations. Provided constructive recommendations to support business development, enhance long-term value creation and competitiveness, and promote transparent, accountable, and fair operations in accordance with good corporate governance principles, with due consideration for all stakeholders to support the Company's sustainable growth.

**Information on individuals nominated for appointment as directors in place of those whose terms have expired (Attachment No. 5)**

Name-Surname	:	Dr. Rachanee O-Charoen	
Age	:	78 years	
Nationality	:	Thai	
Type of Directorship	:	Director	
Current Position	:	Director / Executive Director / Chief Medical Officer	
Date of Appointment as Director	:	27 July 2022 - Present	
Years of Directorship	:	3 years and 8 months (as of the Annual General Meeting of Shareholders)	
Education	:	Bachelor of Medicine, Chulalongkorn University	
Expertise	:	Medical / Quality Management / Risk Management	
Training	:	2025 IFRS S1 and IFRS S2 Risk Disclosure Seminar, organized by the Risk Management and Internal Control Club, Thai Listed Companies Association 2024 AABB Annual Meeting, American Association of Blood Banks 2022 ISO 15189:2012 Medical laboratories - Requirements for quality and competence, ISO 15190:2020 Medical laboratories - Requirements for safety ISO/IEC 19011:2018 Guidelines for auditing management systems Office of Laboratory Standards, Department of Medical Sciences Role of NBC in Hemophilia: 35-year history National Blood Centre, Thai Red Cross Society	
Director Training Program	:	2021 Introduction to PDPA and its Awareness for Organization Class 6 Director Briefing - What Your Board Needs to Know about C-Suite Succession in time of Uncertainty Class 7 2020 Director Accreditation Program (DAP) Class 174 2019 How to Develop a Risk management Plan (HRP) Class 25	
Work Experience (Past 5 Years)	:	2019 - Present: Director Medeze Group Public Company Limited	

- : 2018 – Present Chief Medical Officer  
Medeze Group Public Company Limited
- : 2001 - 2006: Director  
National Blood Centre, Thai Red Cross Society
- : 2007 – 2008 Advisor  
National Center for Genetic Engineering and Biotechnology  
(BIOTEC)

---

**Meeting Attendance in 2024** : Board of Directors’ Meetings: 6/6 meetings (100%)  
Executive Committee Meetings: 40/41 meetings (96.56%)

---

**Shareholding in the Company** : -None-

- Held by the director : -None-
- Held by Spouse/Minor Children : -None-

---

Director Nominee	Other Listed Companies		Other Non-Listed Companies		Positions in Competing / Related Businesses
	No.	Position	No.	Position	
Dr. Rachanee O-Charoen	-None-	-None-	-None-	-None-	-None-

#### Director Qualifications

- The nominee possesses all qualifications as required by applicable laws and relevant regulations. Details are provided below.\*

#### Performance in 2025

- 1) Contributed to the formulation of the Company’s policies, vision, mission, and strategic business plans, ensuring alignment with the Company’s vision: “To be the most reliable advanced cell banking service provider in Asia.”
- 2) Promoted good corporate governance and business ethics, ensuring compliance with applicable laws, regulations, and relevant requirements, while safeguarding the best interests of shareholders and all stakeholders.
- 3) Oversaw and monitored the Company’s performance to ensure alignment with established targets, as well as compliance with applicable laws and regulations. Provided constructive recommendations to support business development, enhance long-term value creation and competitiveness, and promote transparent, accountable, and fair operations in accordance with good corporate governance principles, with due consideration for all stakeholders to support the Company’s sustainable growth.

**Information on individuals nominated for appointment as directors in place of those whose terms have expired (Attachment No. 5)**

Name-Surname	:	Ms. Danita Phithaknetikun	
Age	:	49 Years	
Nationality	:	Thai	
Type of Directorship	:	Director	
Current Position	:	Director / Executive Director / Chief Business Development Officer	
Date of Appointment as Director	:	27 July 2022 - Present	
Years of Directorship	:	3 years and 8 months (as of the Annual General Meeting of Shareholders)	
Education	:	Bachelor of Science, University of the Thai Chamber of Commerce	
Expertise	:	Sales and Marketing / Management	
Training	:	2025 Enhancing the Role of the Audit Committee for Transparency and Stakeholder Confidence, organized by the Thai Institute of Directors Association (IOD) and the Stock Exchange of Thailand (SET).	
	:	2024: Small-Cap Investment Strategies for Sustainable Returns, organized by CSI Investment Institute	
Director Training Program	:	2019 Director Accreditation Program (DAP) Class 164	
Work Experience (Past 5 Years)	:	2019 - Present Director Chief Business Development Officer Medeze Group Co., Ltd.	
	:	2014-2018 Marketing Manager Medeze Group Co., Ltd.	
Meeting Attendance in 2024	:	Board of Directors' Meetings: 6/6 meetings (100%) Executive Committee Meetings: 41/41 meetings (100%)	
Shareholding in the Company	:	643,734,857 shares (representing 60.2748% of all voting shares)	

- Held by the director : 10,726,800
- Held by Spouse/Minor Children : 272,307,800
- Held by a corporate entity : 360,700,257

Director Nominee	Other Listed Companies		Other Non-Listed Companies		Positions in Competing / Related Businesses
	No.	Position	No.	Position	
Ms. Danita Phithaknetikun	-None-	-None-	-None-	-None-	-None-

#### Director Qualifications

- The nominee possesses all qualifications as required by applicable laws and relevant regulations. Details are provided below.\*

#### Performance in 2025

- 1) Contributed to the formulation of the Company's policies, vision, mission, and strategic business plans, ensuring alignment with the Company's vision: "To be the most reliable advanced cell banking service provider in Asia."
- 2) Promoted good corporate governance and business ethics, ensuring compliance with applicable laws, regulations, and relevant requirements, while safeguarding the best interests of shareholders and all stakeholders.
- 3) Oversaw and monitored the Company's performance to ensure alignment with established targets, as well as compliance with applicable laws and regulations. Provided constructive recommendations to support business development, enhance long-term value creation and competitiveness, and promote transparent, accountable, and fair operations in accordance with good corporate governance principles, with due consideration for all stakeholders to support the Company's sustainable growth.